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Inhibitors of Dipeptidyl Peptidase IV-Like
Activity Mediate Antifibrotic Effects in Normal
and Keloid-Derived Skin Fibroblasts
Anja Thielitz1, Robert W. Vetter1, Bianca Schultze2, Sabine Wrenger2, Luca Simeoni2, Siegfried Ansorge3,
Klaus Neubert4, Ju¨rgen Faust4, Petra Lindenlaub1, Harald P. M. Gollnick1 and Dirk Reinhold2
Suppression of collagen and matrix synthesis and inhibition of the fibrogenic cytokine transforming growth
factor-b1 (TGF-b1) is a major therapeutic goal in the treatment of fibrosis and keloids. Inhibitors of dipeptidyl
peptidase IV (DP IV)-like activity affect cell growth and cytokine production and are currently under
investigation for the treatment of metabolic, autoimmune and inflammatory diseases. We show here that the
inhibitors of DP IV-like activity, Lys[Z(NO2)]-thiazolidide and Lys[Z(NO2)]-pyrrolidide, suppress proliferation in
human skin fibroblasts and keloid-derived skin fibroblasts in vitro. They significantly decrease TGF-b1
expression and secretion of procollagen type I C-terminal peptide in supernatants of both cell types.
Furthermore, they abrogate the TGF-b1-induced stimulation of collagen synthesis, matrix deposition, and TGF-b1
and fibronectin expression. Both inhibitors lead to dephosphorylation of mitogen-activated protein kinases
pp38 and pERK1/2, which are activated upon TGF-b1 stimulation and have been implicated in fibrogenesis. In a
mouse model of dermal fibrosis, induced by repetitive intracutaneous injections of TGF-b1, the profibrotic
effect of TGF-b1 detected by dermal thickening, collagen I, and a-smooth muscle actin expression, is
significantly suppressed in the presence of inhibitors. Inhibition of DP IV-like enzymatic activity may therefore
represent a promising therapeutic approach for the treatment of fibrotic skin disorders and keloids.
Journal of Investigative Dermatology (2008) 128, 855–866; doi:10.1038/sj.jid.5701104; published online 18 October 2007
INTRODUCTION
Fibrosis and sclerosis of the skin and subcutaneous tissue can
be seen in a variety of disorders such as keloids, hypertrophic
scars, morphea, systemic sclerosis, eosinophilic fasciitis,
sclerodermic graft-versus-host disease, and other patho-
logical conditions influenced by toxic or pharmacological
factors, for example, toxic-oil-syndrome or eosinophilia
myalgia. The major pathogenetic feature of fibrosis is
represented by excessive accumulation of collagen and
extracellular matrix (ECM), leading to progressive organ
dysfunction in liver, lung, kidney, or skin (Chapman,
2004; Al Attar et al., 2006; Gressner and Weiskirchen,
2006; Liu, 2006). Transforming growth factor-b1 (TGF-b1) has
been identified as a central player in the induction and
aggravation of fibrosis (Blobe et al., 2000; Leask and
Abraham, 2004).
In keloid-derived skin fibroblasts (KFs), TGF-b1 expression
and the response to TGF-b1-induced stimulation of prolifera-
tion, collagen, and fibronectin production are increased as
compared with normal fibroblasts (Babu et al., 1992;
Bettinger et al., 1996; Fujiwara et al., 2005). These data
together with the observation that a TGF-b1-neutralizing
antibody-reduced scarring (Shah et al., 1995) suggest a
crucial role of TGF-b1 in the development of keloids and
scarring. Furthermore, alterations in the expression and
signalling of this cytokine have been implicated in sclero-
derma pathogenesis (Varga and Abraham, 2007). Therefore,
therapeutic strategies antagonizing the strong fibrogenic
effect of TGF-b1 are regarded as a promising approach
to prevent the development and progression of keloids,
scleroderma, and other fibrotic disorders (Gressner and
Weiskirchen, 2006; Leask, 2006).
The dipeptidyl peptidase IV (EC 3.4.14.5, dipeptidyl
peptidase IV (DP IV), CD26) is a homodimeric type II
transmembranic glycoprotein (Fleischer, 1994) that belongs
to the group of postproline dipeptidyl aminopeptidases
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consisting of the gene family of DP IV; fibroblast activation
protein-a (FAP-a); dipeptidyl peptidases DP8 and DP9; and
DP II (Gorrell, 2005). It is a serine exopeptidase catalyzing
the release of N-terminal dipeptides from oligo- and polypeptides
preferentially with proline in the penultimate position, which
results in playing a key role in the catabolism of a number
of neuropeptides, immunopeptides and peptide hormones
(De Meester et al., 1999; Lambeir et al., 2003). Furthermore,
DP IV functions as a binding protein for fibronectin, collagen
and adenosin deaminase and, in association with seprase
(FAP-a), plays a role in tissue invasion and matrix degradation
(Ghersi et al., 2002). Interestingly, it was found that the
pharmacological inhibition of DP IV-like activity affects
growth, cytokine production, and typical functions of
peripheral T cells (Reinhold et al., 2002), keratinocytes, and
sebocytes in vitro (Reinhold et al., 1998; Thielitz et al., 2007).
In vivo, inhibitors of DP IV-like activity have potent
immunosuppressive and anti-inflammatory effects in many
pathological conditions such as murine experimental auto-
immune encephalomyelitis (Steinbrecher et al., 2001),
collagen- and alkyldiamone-induced arthritis (Tanaka et al.,
1997), or rat cardiac and lung transplantation (Korom et al.,
1997; Jung et al., 2006). Currently, the clinical efficacy of DP
IV inhibitors is under investigation for the treatment of type 2
diabetes, as well as multiple sclerosis, rheumatoid arthritis,
colitis ulcerosa, psoriasis, and acne.
A major concern for the systemic use of inhibitors of DP
IV-like activity is the possible induction of fibrosis via the
temporary induction of TGF-b1 in T cells (Reinhold et al.,
1997). However, despite the fact that TGF-b1 plasma levels
were increased and discussed to be responsible for various
immunosuppressive effects, no fibrotic conditions have been
observed in treated animals (Steinbrecher et al., 2001). To
date, only few investigations are available on the effects of
DP IV inhibitors on fibroblast activity. Most importantly, it is
not known whether inhibition of DP IV-like activity induces
pathological changes in fibroblast function that could result
in the generation of fibrosis. A previous investigation
suggesting a suppressive effect of DP IV inhibitors on
platelet-derived growth factor-stimulated fibroblast activity
(Williams et al., 2003) prompted us to deeper investigate the
role of inhibitors of DP IV-like activity in skin fibroblast
biology. This is also of interest because these substances are
discussed as promising tools for the treatment of inflamma-
tory or hyperproliferative skin diseases.
Here we show that the inhibitors of DP IV-like
activity, Lys[Z(NO2)]-thiazolidide (LZNT) and Lys[Z(NO2)]-
pyrrolidide (LZNP), suppress proliferation, TGF-b1 and
fibronectin expression, procollagen type I C-terminal
peptide (PICP) secretion, as well as collagen and matrix
deposition of normal skin fibroblasts (NFs) and KFs in vitro.
Furthermore, they abrogate TGF-b1-induced profibrotic ef-
fects in vitro and, as shown in a mouse model of cutaneous
fibrosis, in vivo.
Our data provide early evidence that DP IV-like activity is
involved in the regulation of major fibroblast functions, and
may represent a promising pharmacological target in the
treatment of keloids and fibrotic or sclerotic diseases.
RESULTS
Expression of DP IV and related enzymes on NFs and KFs skin
fibroblasts
As it is known that DP IV is upregulated upon activation in
T cells and keratinocytes (Novelli et al., 1996; De Meester
et al., 1999), we were interested to see whether DP IV
expression was altered in KFs compared with NFs. We
investigated DP IV expression of NFs and KFs of six different
donors grown by explant cultures. Flow cytometric analysis
revealed that 73716% of NF express DP IV, a proportion
significantly higher (Po0.01) than that of KF (46725%)
(Figure 1b). Accordingly, the DP IV-like enzymatic activity
(Figure 1a) detected by Gly–Pro–pNA-hydrolyzing activity
was also higher in NF (83724 pkat/106 cells) as compared
with KF (48726 pkat/106 cells). Gly–Pro–pNA is also hydro-
lyzed by DP8 and DP9, which are localized in the cytoplasm,
and, with a 100-fold weaker catalytic efficiency (Aertgeerts
et al., 2005), by FAP-a. We found no difference in the
qualitative mRNA expression of DP IV-like proteins FAP-a,
DP 8, DP 9 between NF and KF of five different donors
(Figure 1c). In cell suspensions of permeabilized cells as well
as in cell homogenates, we found no significant difference of
DP IV-like activity and its suppression by LZNP and LZNT as
compared with native cells. Thus, we conclude that both the
substrate and the inhibitors enter the cells and that the DP IV-
like enzyme activity we measure results from DP IV on the
surface, dipeptidyl peptidase 8 and/or 9 in the cytoplasm,
and, to a negligible extent, from FAP-a. Surface expression of
FAP-a was equal in both cell types (49710 vs 5176%,
respectively; data not shown).
Inhibitors of DP IV-like activity suppress enzymatic activity and
proliferation of NF and KF in vitro
We found that the inhibitors LZNT and LZNP, used in
concentrations of 0.1–10 mM, significantly (Po0.05) suppress
enzymatic activity of NF (Figure 2a) and KF (Figure 2b) in a
dose-dependent manner. Inhibitors of DP IV-like activity are
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Figure 1. Expression of DP IV/CD26 and related enzymes on NF and KFs.
(a) The DP IV-like activity was measured by Gly–Pro–4-nitroanilide hydrolysis.
(b) DP IV surface expression was detected by flow cytometry. The data are
presented as mean7SD (n¼6 in each group; *Po0.05, **Po0.01, Student’s
t-test). (c) mRNA expression of DP IV and DP IV-like enzymes. Enzymatic
amplification was performed on cDNA derived from 70–80% confluent cell
cultures (1¼NF; 2–6¼KF of five different donors).
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known to influence proliferation in various cell types.
Therefore, we were interested to test whether the proliferation
of fibroblasts was also suppressed in the presence of our
inhibitors.
The DNA synthesis of normal and KFs was dose
dependently suppressed after 24 hours of incubation (Figure
2c and d), in the presence of different inhibitor concentra-
tions (3.125–50 mM), as compared with control cultures
without inhibitor. In both cell types, effects on DNA synthesis
were only moderate with a maximum of 30–40% inhibition.
A possible cytotoxic effect of the inhibitors at the
concentrations used could be excluded using the lactate
dehydrogenase cytotoxicity detection assay, and Trypan blue
staining demonstrated that more than 95% of cells are viable
in all culture systems 6 hours after incubation (data not
shown).
Inhibitors of DP IV-like activity decrease TGF-b1 production in
NFs and KFs
An important property of TGF- b1 in the induction of fibrosis
is its capability to activate its own mRNA expression and
thereby increase its own secretion (Kim et al., 1990). We
show here that basal production of latent TGF-b1 is
significantly suppressed in the presence of LZNP and LZNT
after 72 hours of incubation in both NF (Po0.05) and KF
(Po0.001) (Figure 3). The decrease was clearly time
dependent, with a minor effect already after 24 hours, a
significant, but modest effect after 48 hours (data not shown),
and a maximum effect after 72 hours. To mimic pathological
conditions in which fibrosis is induced by increased TGF-b1
expression, we stimulated our cultures by the addition of
10 ng/ml of TGF-b1. As shown in Figure 3, 72 hours after
stimulation the TGF-b1 expression in supernatants was
increased 4- to 5-fold. Control experiments were performed
to exclude that the TGF-b1 measured was the originally
added ‘‘active’’ cytokine. Active TGF-b1 could be detected
only in the first five minutes after it was added to the cultures,
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Figure 2. Suppression of enzymatic activity and proliferation of NFs and KFs in the presence of inhibitors. The inhibitors of DP IV-like activity, LZNP
and LZNT, dose dependently reduce enzymatic activity (Gly–Pro–4-nitroanilide hydrolysis) in NF (a) and KF (b) (both Po0.05). The data are presented as
mean7SEM of four independent experiments. (c and d) The DNA synthesis measured by [3H]thymidine incorporation was significantly suppressed
compared with control cultures in NFs (c) and KFs (d) at concentrations of 12.5 mM or higher. The DNA synthesis values are expressed as percentage of
[3H]thymidine incorporation in relation to control cultures without inhibitor (100%¼ 5,69172,300 c.p.m. (NF) or 100%¼ 3,1677674 (KF)), and represent
the mean7SEM of six independent experiments. Statistics were calculated by linear regression analysis (a and b) or by one-way analysis of variance
(*Po0.05, **Po0.01 vs control, Tukey’s multiple comparison test).
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Figure 3. DP IV inhibitors induce decreased production of latent TGF-b1 in
NFs and KFs. NFs and KFs were incubated with the inhibitors LZNT and LZNP
(50mM), or with TGF-b1 (T) (10 ng/ml), or TGF-b1 and one inhibitor. After
72 hours, supernatants were harvested and the production of latent TGF-b1
was measured. TGF-b1 alone used as autostimulation factor of TGF-b1
production served as a positive control. The data represent the mean7SEM
of four independent experiments. Statistics were calculated by one-way
analysis of variance (*Po0.05, **Po0.01, ***Po0.001, Tukey’s multiple
comparison test).
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thus confirming that the cytokine measured after 72 hours
represents the latent TGF-b1 produced by the cultured cells
(data not shown). The inhibitors of DP IV-like activity
significantly abrogate the TGF-b1-induced stimulation of
TGF-b1 autoproduction both in NFs (Po0.01) and KFs
(Po0.001) (Figure 3).
We have next investigated whether the modulatory
activity of inhibitors of DP IV-like activity on TGF-b1
expression is regulated at the transcriptional level. NFs were
incubated with DP IV inhibitors LZNT or LZNT for 4, 24, and
48 hours. The relative mRNA levels of TGF-b1 were subse-
quently determined by quantitative real-time PCR. Neither
LZNT nor LZNP caused a significant reduction in the
relative levels of the TGF-b1 mRNA at 4 or 24 hours,
thus suggesting that inhibitors of DP IV-like activity do not
directly regulate TGF-b1 transcription. However, we found a
significant suppression of TGF-b1 mRNA after 48 hours
(data not shown).
Inhibition of DP IV-like activity leads to suppression of collagen
and matrix deposition in TGF-b1-stimulated fibroblasts
Increased collagen and matrix deposition are key features
of fibrosis and keloids. [3H]Proline incorporation assays
were performed to characterize the ECM production by
NFs and KFs. No significant differences were found between
basal production of NFs and KFs, and between control
cultures and inhibitor-treated cultures (Figure 4a and b).
After stimulation with 10 ng/ml TGF-b1, in both cell types
a strong increase of collagen (NF 3; KF 4) and
matrix deposition (NF 1.5; KF 3) was found, which
was more pronounced in KFs. When LZNP and LZNT
were added together with TGF-b1, the TGF-b1-induced
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Figure 4. Suppression of collagen and matrix deposition, PICP synthesis, and fibronectin expression in NFs and KFs. (a and b) Regulation of collagen and
matrix deposition in NFs (a) and KFs (b) in the presence of inhibitors LZNT or LZNP (50mM), and after stimulation with TGF-b1 (T) at 10 ng/ml in the presence
or absence of inhibitors (t¼ 72 hours). The data represent the mean7SEM of six independent experiments. (c and d) Inhibitor-mediated suppression of
PICP secretion induced by TGF-b1 in NF (c) or KF (d). (e and f) Inhibitor-mediated suppression of fibronectin expression induced by TGF-b1 in NF (e) or KF (f).
NF or KF were left untreated or incubated for 72 hours with 10 ng/ml TGF-b1 (T), inhibitors LZNP or LZNT at 50mM, or both substances. Statistics were calculated
by one-way analysis of variance (*Po0.05, **Po0.01, ***Po0.001, Tukey’s multiple comparison test).
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stimulation was completely and significantly abrogated in
both cell types.
Inhibition of DP IV-like activity leads to suppression of collagen
synthesis
To further substantiate the effects of inhibitors of DP IV-like
activity on collagen synthesis and/or secretion, we deter-
mined the amount of PICP in the culture media of NFs or KFs
incubated with TGF-b1 and DP IV inhibitors LZNT or LZNP
alone, or a combination of TGF-b1 and one of the inhibitors.
TGF-b1 significantly (Po0.01) stimulated PICP secretion as
compared with control cultures in NFs (1,3507311 vs 2,0427
340ng/ml) and KFs (1,4597166 vs 1,9337270ng/ml).
We found that the PICP secretion by NFs and KFs was
significantly lowered in the presence of inhibitors alone
compared with control cultures without inhibitor or cultures
stimulated with TGF-b1 (Figure 4c and d). Quantitative real-
time PCR experiments showed no significant suppression of
mRNA production of collagens I (a1 and a2) and III (a1) after
12 hours incubation in the presence of inhibitors (data not
shown).
Inhibition of DP IV-like activity suppresses the TGF-b1-induced
stimulation of fibronectin expression
To further elucidate inhibitor effects on ECM, we investigated
fibronectin expression in culture supernatants obtained
72 hours after inhibitor or TGF-b1 were added to the cultures.
No significant differences were found between basal fibro-
nectin expression in NF and KF supernatants and between
control cultures and inhibitor-treated cultures, except for
LZNT-treated cultures in NF (Figure 4e and f). After
stimulation with 10 ng/ml TGF-b1, in both cell types a
significant increase of fibronectin (NF 1.6; KF 2.3) was
found, which was more pronounced in KFs. When LZNP and
LZNT were added together with TGF-b1, the TGF-b1 induced
stimulation was significantly suppressed in both cell types.
DP IV inhibitors abrogate the TGF-b1-induced alteration
of MMP expression
TGF-b1 is known to regulate matrix- and collagen-degrading
proteases (Ravanti et al., 1999; Saed et al., 2000). Using a
commercially available matrix metalloproteinase (MMP)
antibody array, we next investigated whether the expression
of MMPs, or their inhibitors, tissue inhibitors of metallopro-
teinases (TIMPs), is influenced by inhibitors of DP IV-like
activity, and thereby contributes to the observed inhibitor
effects on collagen and matrix deposition. Figure 5 shows the
results of the MMP antibody array from NFs left untreated or
incubated with TGF-b1, the inhibitor LZNP, or a combination
of both. Similar experiments were performed with KFs and
the other inhibitor, LZNT. A relative semi-quantitative
analysis of dot size and intensity (summarized in Table 1)
revealed that TGF-b1 upregulates several metalloproteases
(MMP-2, MMP-8, MMP-10, MMP-13) in KFs and NFs. In the
presence of inhibitors of DP IV-like activity, the stimulatory
effect of TGF-b1 on MMP-2 and MMP-13 expression was
diminished, whereas inhibitors alone slightly suppressed
MMP-1 and MMP-2 expression. We found no relevant
changes in the expression of TIMPs 1–4.
Inhibition of DP IV-like activity leads to dephosphorylation
of p38-MAPK and pERK1/2
To further clarify the underlying mechanisms of the relation-
ship between DP IV-like activity and fibroblast functions, we
next investigated whether the phosphorylation status of the
mitogen-activated protein kinases (MAPKs) p38 and ERK1/2 is
influenced in the presence of inhibitors. The rationale for
these experiments was that inhibitors of DP IV-like activity
were previously shown to affect ERK1/2 and p38 activation in
lymphocytes (Ka¨hne et al., 1999), and that both kinases were
implicated in the regulation of collagen and matrix metabo-
lism (Sato et al., 2002; Li et al., 2006). We first performed
experiments to investigate time-dependent effects (data not
shown) and found that a maximum suppression of p38 and
ERK1/2 phosphorylation was observed 60–120minutes after
the DP IV inhibitors LZNP and LZNT were added. At the
same time points, maximum stimulatory effects on p38 and
ERK1/2 phosphorylation were observed after addition of
TGF-b1. Figure 6 shows that inhibition of DP IV-like activity
downregulates phospho-p38 (pp38) and phospho-extracellu-
lar signal-related kinase 1/2 (pERK1/2) compared with
unstimulated control cells, and abrogates the TGF-b1-
induced stimulation of the phosphorylation of both kinases
(t¼ 90minutes). This is shown in NFs (Figure 6a) and KFs
(Figure 6b). As Smad3 has been shown to be a key mediator
of TGF-b1-induced fibrotic effects, we also investigated
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Figure 5. Results of the human MMP antibody array. NFs were cultured in DMEM supplemented with 0.1% FCS and left untreated (a), treated with
TGF-b1 10 ng/ml(b), with LZNP (50 mM) (c) or a combination of TGF-b1 and LZNP (d). Supernatants obtained after 72 hours of incubation were analyzed by the
MMP antibody array (layout listed above).
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whether pSmad3 activation was influenced in the presence of
LZNP or LZNT. After 90minutes of incubation, we found no
differences between inhibitor-treated and control cultures
with or without TGF-b1 (data not shown). All TGF-b1-treated
cultures showed a strong pSmad3 activation. We conclude
that our inhibitors do not act via interaction with the Smad
pathway.
Antifibrotic effect of inhibitors of DP IV-like activity in vivo
To examine the in vivo relevance of our findings, we used an
animal model in which cutaneous fibrosis is induced by
repetitive intracutaneous injections of high doses of TGF-b1
(Shinozaki et al., 1997; Bo¨hm et al., 2004). In this model,
newborn mice are used because of their lower collagen
content in the skin compared with adult mice, thus rendering
Table 1. Results of a semi-quantitative comparative analysis of MMP array membranes
MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-10 MMP-13 TIMP-1 TIMP-2 TIMP-3 TIMP-4
NF
TGF-b1 2 m 2 mm 2 m m 2 2 2 2
LZNP k kk 2 2 2 2 2 2 k kk 2
LZNT k k 2 2 2 2 2 2 2 ND 2
TGF-b1+LZNP k 2 k 2 k 2 k 2 2 2 2
TGF-b1+LZNT k 2 k 2 2 2 k 2 2 ND 2
KF
TGF-b1 2 m 2 m 2 m m 2 2 m k
LZNP 2 k 2 2 2 2 2 2 2 2 2
LZNT k kk 2 k k 2 k k 2 ND k
TGF-b1+LZNP 2 2 2 2 2 2 2 2 2 m k
TGF-b1+LZNT kk 2 2 2 2 2 2 2 2 ND 2
KF, keloid-derived skin fibroblast; LZNP, Lys[Z(NO2)]-pyrrolidide; LZNT, Lys[Z(NO2)]-thiazolidide; MMP, matrix metalloproteinase; NF, normal skin
fibroblast; TGF-b1, transforming growth factor-b1; TIMP, tissue inhibitor of metalloproteinase.
The relative changes compared with control membranes left untreated are summarized (2 0.61–1.5 ; m 1.51–3.0 ; mm43.0 ; k 0.2–0.6 ; kko0.2;
=fold control; ND=not done). The framed boxes correspond to the shown membranes.
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them more sensitive for fibrogenic stimuli. Newborn mice
were injected into the neck on three consecutive days with
TGF-b1 (800 ng), or LZNT or LZNP (100 mM) plus TGF-b1, or
phosphate-buffered saline (PBS). On day 4, punch biopsies
were taken from the injection sites and subjected to
histological analysis (Figure 7a–l). As it is likely that fibrosis
contributes to increased dermal thickness, we used histome-
trical analysis to assess the effect of inhibitors of DP IV-like
activity on TGF-b1-induced skin fibrosis. When compared
with PBS alone, injections with TGF-b1-induced dermal
thickening (Table 2) as well as increased numbers of collagen
fibers as shown by Van Gieson staining and by immuno-
histochemistry using an anti-collagen type I antibody (Figure
7a–c vs d–f) and an a-smooth muscle actin antibody (Table 2).
Injections with inhibitors alone did not produce significant
changes as compared with mice treated with PBS/BSA (data
not shown). Simultaneous injection with TGF-b1 plus LZNP
or LZNP resulted in a significant reduction in dermal
thickening as compared with mice injected with TGF-b1
alone (Figure 7d–f vs g–i or j–k; Table 2). These results confirm
the anti-fibrogenic activity of inhibitors of DP IV-like activity
in vivo.
DISCUSSION
The data presented here provide early evidence that
inhibitors of DP IV-like activity suppress fibroblast prolifera-
tion in normal and KFs, decrease TGF-b1 expression, and
abrogate the TGF-b1-mediated stimulatory effects on TGF-b1
and fibronectin production, collagen synthesis, and matrix
deposition.
TGF-b1 has been identified as a key mediator in the
generation of fibrosis with pleiotropic effects, among which
are the increase of collagens type I, III, VI, VII, X, fibronectin,
proteoglycans, fibrogenic growth factors such as connective
tissue growth factor, or the inhibition of matrix degradation
by regulating the synthesis of proteases and their inhibitors
a b c
d e f
g h i
j k l
Figure 7. Suppression of TGF-b1-induced skin fibrosis in vivo. Cutaneous fibrosis in newborn mice was induced by repetitive TGF-b1 injections. Mice
were injected on three consecutive days intracutaneously in the neck with PBS/BSA (a–c), 800 ng TGF-b1 (d–f), or TGF-b1 plus 50 mM of LZNT (g–i) or LZNP
(j–l). On day 4, mice were killed, and 4-mm punch biopsies were taken from the sites of injection. Paraffin-embedded biopsies were processed for hematoxylin
and eosin staining (a, d, g, j), van Gieson staining (b, e, h, k) in which collagen fibers appear red, and immunohistochemistry using an antibody against
collagen type I (c, f, i, l), in which bound antibodies were visualized by the immunoperoxidase technique (red, immunoreactivity). Bar¼50 mm.
Magnification,  200.
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(Leask and Abraham, 2004). However, to our knowledge, in
contrast to the related FAP-a (Gorrell, 2005), DP IV has never
been shown to be associated with the development of
fibrosis.
KFs can be considered as ‘‘activated’’ fibroblasts, as they
show an increased proliferation rate and increased sensitivity
toward TGF-b1-mediated effects on collagen and matrix
production as compared with NFs (Babu et al., 1992;
Bettinger et al., 1996). As DP IV expression was shown to
be upregulated upon activation in T cells and keratinocytes
(Novelli et al., 1996; De Meester et al., 1999), we were
interested to see whether DP IV expression was altered in KFs
compared with NFs. We found a moderate but significantly
lower DP IV-like activity and DP IV surface expression in KFs,
which had no impact on inhibitor-mediated effects; the
antiproliferative activity of DP IV inhibitors as well as the
effects on TGF-b1 expression and collagen and matrix biology
were comparable in both cell types. However, as decreased
DP IV expression has also been associated with higher
invasive potential in malignant cells (Pethiyagoda et al.,
2000; Kikkawa et al., 2005; Sato et al., 2005), it might be
possible that DP IV expression is functionally related to the
‘‘invasive’’ phenotype of keloids.
It has been previously shown (Lankas et al., 2005) that our
inhibitors LZNP and LZNT are not selective for DP IV and
also inhibit the cytoplasmic DP IV-like enzymes DP8 and
DP9 and, with a 100-fold less intensity, FAP-a. Although
FAP-a is probably not a target of LZNP or LZNT in the
concentrations used in our experiments, it can presently not
be excluded that DP8 or DP9 or other yet unknown DP IV-
like enzymes are involved in mediating the observed
biological effects. The possible contribution of intracellular
targets also provides an explanation for discrepancies
between concentrations needed to suppress enzyme activity
and those mediating biological effects, which are usually
5- to 10-fold higher.
The detailed and comprehensive mechanisms of how
LZNT and LZNP affect fibroblast functions are yet unclear.
The most relevant findings of our study are that these
inhibitors significantly suppress TGF-b1 auto-production of
fibroblasts, without directly regulating mRNA expression, and
that they reduce TGF-b1-stimulated phosphorylation of
phospho-p38 mitogen-activated protein kinase and pERK
without affecting pSMAD3 phosphorylation. The observed
decreased mRNA expression at late time points (48 hours)
might also result from the activation or inactivation of other
yet unidentified cofactors induced upon inhibitor incubation,
or be a consequence of cell cycle arrest.
Inhibition of ERK activation leads to decreased fibroblast
proliferation (Martinez-Salgado et al., 2006). Therefore, the
suppression of ERK phosphorylation is probably involved in
mediating the antiproliferative effects of inhibitors of DP IV-
like activity in fibroblasts. Interestingly, the basal inhibitor-
induced suppression of pERK and proliferation is slightly
more pronounced in keloids, whereas the suppression of
TGF-b1-stimulated pERK is diminished as compared with
NFs. This observation suggests that ERK activation is not
mainly responsible for the previously described increased
proliferation of KFs toward TGF-b1 (Bettinger et al., 1996).
Furthermore, p38 was shown to regulate collagen synthesis,
matrix deposition, and MMP production in fibroblasts (Sato
et al., 2002; Munshi et al., 2004; Li et al., 2006), and belongs
to the SMAD-independent pathway of the TGF-b1-signalling
cascade. Moreover, DP IV has been shown to mediate cell
adhesion to fibronectin and collagen I through p38-MAPK-
regulated phosphorylation of integrin b1 in the Karpas 299
T-anaplastic large-cell lymphoma line (Sato et al., 2005).
Thus, the suppression of p38 phosphorylation by inhibitors
of DP IV-like activity provides one possible mechanism of
how antifibrotic effects of these substances are mediated.
Surprisingly, the inhibitor sensitivity of the p38 pathway is
much increased in KFs as compared with NFs, whereas the
effects on collagen and matrix metabolism are comparable in
both cell types, which suggests an indirect or complex
relationship. If p38 contributes to increased collagen
production of keloids, the inherent inhibitor sensitivity of
this pathway would be helpful for therapy by targeting the
altered cells more selectively.
A special characteristic of keloid invasiveness is an
increased migratory activity associated with higher MMP-1
(interstitial collagenase) and MMP-2 (gelatinase-A) produc-
tion (Fujiwara et al., 2005). TGF-b1 is known to induce
expression of MMP-2, MMP-9, and MMP-13 in fibroblasts
(Ravanti et al., 1999; Saed et al., 2000), whereas MMP-1
expression is negatively regulated through SMAD3 and 4
(Yuan and Varga, 2001). Using an antibody array with
subsequent semi-quantitative analysis, we have largely
reproduced these stimulating effects of TGF-b1 on MMP-2
and MMP-13 in both KFs and NFs and, in addition, found a
previously unknown stimulatory activity on MMP-8 expres-
sion in both cell types. In the presence of inhibitors of DP IV-
like activity, the stimulatory effect of TGF-b1 on MMP-2 and
MMP-13 expression was diminished, whereas DP IV inhibi-
tors alone slightly reduced MMP-1 and MMP-2 expression.
This might have an impact on keloid migratory activity,
which has to be further substantiated. The decreased MMP
expression suggests that reduced collagen synthesis rather
Table 2. Antifibrotic effect of DP IV inhibitors in a
mouse model of cutaneous fibrosis
PBS T T+LZNP T+LZNT
Dermal thickness
(mm)
191726a 241757 202733a 213734b
a-SMA expression 976a 3077 2376b 2279b
DP IV, dipeptidyl peptidase IV; LZNP, Lys[Z(NO2)]-pyrrolidide; LZNT,
Lys[Z(NO2)]-thiazolidide; PBS, phosphate-buffered saline; a-SMA,
a-smooth muscle actin; T, TGF-b1.
aPo0.001 versus T; bPo0.01 versus T.
The antifibrotic effect of LZNP and LZNT (50 mM) injected with TGF-b1
(10 ng/ml) was quantified using the vertical dermal thickness as an
indicator for fibrosis. The data represent the mean7SD of 40 measure-
ments taken from the central part of the biopsies of four different animals
in each group (10 measurements per animal). The number of immunor-
eactive cells was determined in 44 viewing areas of deparaffinized skin
sections stained for a-smooth muscle actin.
Statistics were calculated by one-way analysis of variance.
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than increased collagenolysis mediates the suppression of
collagen deposition in the presence of inhibitors. Although
the results of the array have to be interpreted with caution
and further confirmed by other quantitative methods, these
data suggest that the inhibitor-related effects on fibroblast
functions are mediated by a variety of mechanisms and
cofactors.
Summarizing, the antifibrogenic activity of inhibitors of
DP IV-like activity in vitro and in vivo adds another
dimension to the broad spectrum of possible therapeutic
applications of this promising substance group. Further
investigations will have to clarify the differential contribution
of other DP IV-like proteins to the observed biological effects
and the detailed mechanisms to provide a rationale for
improved molecule- and disease-targeted inhibitor design. It
might be advantageous for these substances that inhibition of
DP IV-like activity interacts only partly with TGF-b1 signal-
ling and that suppression of TGF-b1 production has so far
only been observed in fibroblasts, but not in other immune or
epithelial cells. Broad suppression of this pluripotent and
ubiquitously distributed cytokine could be potentially hazar-
dous if the various physiological roles of TGF-b1 are
considered, for example, immunosuppressive, anti-inflam-
matory, tumor-suppressive, and antiproliferative effects.
MATERIALS AND METHODS
All described studies using materials obtained from human subjects
were conducted according to the Declaration of Helsinki Principles
and approved from the medical ethical committee of the Otto-von-
Guericke University, Magdeburg. Participants gave their written
informed consent.
Sources of fibroblasts
Normal human skin fibroblasts were cultured from discarded tissue
of dermatomed skin from the trunk or thigh of adults of Caucasian
race, through explant culture. Keloids were collected from six
patients of Caucasian origin aged 15–67 years (mean 36.6720 years,
median 35.4 years) who had undergone keloid excision in the
Dermatology Clinic of the Otto-von-Guericke University Magde-
burg, after they had given their written informed consent. All keloids
included in this study were confirmed by histologic examination.
The keloids were obtained from the trunk (n¼ 3), arm (n¼ 2), and
ear lobe (n¼ 1), and grown through explant culture using the second
to sixth passages for the experiments.
Cell culture conditions
Both NFs and KFs were routinely cultured in Iscove’s Medium
supplemented with 1% penicillin/streptomycin and 10% fetal calf
serum (FCS) (all from Biochrom, Berlin, Germany) in a humidified
atmosphere of 5% CO2 at 371C.
For inhibitor experiments, cells were either grown in serum-free
Fibromed-Medium or DMEM, with 3.7 g/l NaHCO3, 4.5 g/l
D-glucose, and glutamine supplemented with 0.1% FCS (both from
Biochrom). LZNP and LZNT were synthesized by K Neubert and
J Faust. Cell viability was determined using the lactate dehydrogenase
cytotoxicity detection kit (Roche Diagnostics, Mannheim, Germany)
at time points of 4 and 6hours after inhibitor incubation and by
Trypan blue (Sigma-Aldrich, Deisenhofen, Germany) staining.
Immunofluorescence staining of cells
Immunofluorescence staining of fibroblasts cells was performed
using the monoclonal anti-CD26 antibody clone M-A261 (mIgG1;
BD Biosciences, Heidelberg, Germany). For control of nonspecific
labelling, cells were incubated with an irrelevant IgG1 monoclonal
mouse antibody (BD Biosciences). Labelled cells were analyzed by
flow cytometry (FACS-Calibur; BD Biosciences).
Enzymatic assay
DP IV-like activity was determined in triplicate in PBS, pH 7.4, using
Gly–Pro–4-nitroanilide (Sigma-Aldrich) as chromogenic substrate.
A 100-ml volume Gly–Pro–4-nitroanilide was added in a concentra-
tion of 3mM to cellular suspensions of 105 cells/100 ml. Reactions
were stopped by adding 900 ml acetate buffer (1 M pH 4.4) either
immediately (control) or after 120minutes of incubation at 371C.
After centrifugation (2minutes, 10,000 g), the absorbance of the
supernatant was detected spectrophometrically at 392 nm.
RNA preparation from NFs and KFs and qualitative RNA
amplification
The RNA preparation was performed as previously described
(Thielitz et al., 2007). A 1.2-ml volume of the reverse transcription
reaction was used as template for amplification. Forty cycles were
performed in a Peltier thermal cycler PTC-200 (Biozym Diagnostik,
Hessisch Oldendorf, Germany) in 50 ml reaction buffer containing
2.5U HotStarTaq DNA Polymerase (Qiagen, Hilden, Germany),
200mM dNTP, and 0.5 mM of the corresponding primer set of DP IV
((50–30) sense GATGCTACA GCTGACAGTCGC, (50–30) antisense
TGGTGACCATGTGACCCACTG); DP8 ((50–30) sense AGATCAACCT
GACCTGGCC, (50–30) antisense ACGGAAGCAGGATCTTCTGG);
DP9 ((50–30) sense TCCAGGTGCAGAAGCACTCG, (50–30) antisense
TAGGGGACACCATGAAGCCG; and FAP-a ((50–30) sense CAAAGA
CCAGGAGATCCACC, (50–30) antisense AACAAAGAATCCACCAG
CCC) obtained from BioTeZ (Berlin, Germany). The initial activation
step at 951C for 15minutes was followed by 40 cycles of
denaturation for 1minute at 941C, annealing for 0.5minutes at
601C, and extension at 721C for 1minute. The reaction was stopped
after a final extension step at 721C for 5minutes and products were
visualized on a 1.5% agarose gel.
Proliferation assay
NFs and KFs were seeded in a concentration of 2 105 cells/ml into
96-well plates (PAA, Co¨lbe, Germany) in serum-free medium.
Different concentrations of the inhibitors (3.125–50mM) LZNT and
LZNP were added after 24 hours to the adherent cells. After 48 hours
the cultures were pulsed for additional 6 hours with [3H]methyl-
thymidine ([3H]dThd, 0.2 mCi per well; ICN, Meckenheim, Ger-
many). The incorporated radioactivity was harvested on glass-fiber
filters and measured by scintillation counting.
TGF-b1 and fibronectin ELISAs
For the generation of supernatants, fibroblasts (NFs and KFs) in a
concentration of 105 cells/ml were seeded in 24-well plates in
culture medium containing 10% FCS. After 24 hours the medium
was exchanged by low-serum medium (DMEM supplemented with
0.1% FCS), and the inhibitors, LZNT or LZNP, in concentrations of
50 mM, TGF-b1 (10 ng/ml), or both, were added. Supernatants were
collected 72 hours after the substances were added. TGF-b1 was
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measured using a commercially available ELISA kit (R&D Systems,
Wiesbaden, Germany). For the analysis of fibronectin, samples were
diluted 40-fold and also measured by a commercially available
ELISA kit (TaKaRa, Shiga, Japan).
Determination of PICP
The amounts of PICP used as a marker for procollagen I secretion
were determined using a commercially available ELISA (TaKaRa).
Fibroblasts (NFs and KFs) were seeded into 12-well tissue culture
plates at a density of 200,000 cells per well. After 24 hours the
medium was exchanged by low-serum medium (DMEM supple-
mented with 0.1% FCS and 100mg/ml L-ascorbic acid). Fibroblasts
were subsequently stimulated with TGF-b1 (10 ng/ml), the DPIV
inhibitors LZNT or LZNT at a concentration of 50 mM, or both agents.
Culture supernatants were harvested after 48 hours, centrifuged, and
frozen at 701C until use.
Determination of collagen and ECM deposition
Collagen secretion and deposition into ECM were assessed by a
proline incorporation assay described in detail earlier (Peterkofsky
and Diegelmann, 1971). All assays were performed in triplicate.
Briefly, 5 104 fibroblasts were seeded into 24-well plates (PAA) in
culture medium containing 10% FCS. After 16 hours the medium
was exchanged by low-serum medium (DMEM supplemented with
0.1% FCS, 100 mg/ml L-ascorbic acid) containing [2,3,4,5-3H]L-
proline (2mCi/ml; NEN, Boston, MA) and the inhibitors LZNT or
LZNP (50 mM), TGF-b1 (10 ng/ml), or both, were added. After
72 hours the culture medium was removed and remaining fibroblasts
were lysed with deionized water (10minutes, room temperature).
ECM was ethanol-fixed (70% ethanol, 15minutes, room tempera-
ture). One half of the wells was incubated with 30U/ml
of collagenase (Clostridium histolyticum; Sigma, Deisenhofen,
Germany) in collagenase assay buffer (50mmol/l Tris-HCl, pH 7.5,
5mmol/l CaCl2, 2.5mmol/l N-ethylmaleimide) for 4 hours at 371C.
The remaining wells were incubated with assay buffer. The
supernatants were removed and residual ECM was solubilized by
overnight incubation in 0.3mol/l of NaOH–1% SDS. Equal aliquots
of supernatants after collagenase digestion and supernatants contain-
ing the residual ECM were subjected to liquid scintillation counting.
The counts measured in supernatants after collagenase treatment
represent the collagen content. [3H]Proline measured after solubi-
lization of the remaining ECM represents non-collagenous ECM. The
total of both counts was equal to the counts from solubilized ECM
without collagenase treatment and represents the total proline
incorporation. Relative ECM synthesis can be calculated by the
established formula (Agelli and Wahl, 1988): ECM¼ c.p.m. in
collagenþ 5.4 c.p.m. in non-collagen ECM. The formula contains
the factor 5.4 to correct the 5.4-fold higher proline or hydroxyproline
content of collagens compared with that of other proteins.
MMP antibody array
Supernatants were prepared as described above for the TGF-b1 ELISA
and collected 72 hours after the inhibitors LZNT or LZNP (50 mM),
TGF-b1 (10 ng/ml), or both, were added. They were analyzed by a
human MMP antibody array (RayBiotech; Norcross, GA) according
to the manufacturer’s instructions.
Semi-quantitative analysis was performed using the software
Kodak D1 3.6, by calculating three times for each dot the product of
size and densitometric intensity after the separate membranes were
normalized to each other using the results for the six positive
controls. The results for each MMP dot are demonstrated relative to
the control membrane (cells without inhibitors or TGF-b1).
Western blotting
Fibroblasts were seeded in a density of 1 105/well and grown for
24 hours in low-serum medium (DMEM supplemented with 0.1%
FCS), which was exchanged by serum-free DMEM 2hours before the
experiment was started. Cells were lysed in lysis buffer containing
1% NP-40, 1% laurylmaltoside (N-dodecyl b-D-maltoside), 50mM
Tris pH 7.5, 140mM NaCl, 10mM EDTA, 10mM NaF, 1mM
phenylmethylsulfonyl fluoride, and 1mM Na3VO4. Cell extracts
were adjusted to represent the same amount of cellular protein
(50 mg), and proteins were separated by SDS–PAGE, electrotrans-
ferred to polyvinylidene difluoride membranes, and blotted with the
following antibodies: rabbit anti-phospho-p44/42-MAPK, rabbit anti-
phospho-p38 MAPK, b-actin antibody (all from Cell Signaling,
Beverly, MA). After three washings with Tris-buffered Saline Tween
20 (TBST), a secondary antibody, conjugated with horseradish
peroxidase, was applied and the signals detected by chemolumines-
cence reagents (Pierce Biotechnology, Rockford, IL).
Mouse model for cutaneous fibrosis
A mouse model for TGF-b1-induced cutaneous fibrosis described
previously (Shinozaki et al., 1997) was used for in vivo evaluation of
the antifibrogenic effect of DP IV inhibitors. The rationale to use this
model was the background that increased TGF-b1 production is
involved in the pathogenesis of keloids and other fibrotic conditions.
Accordingly, cutaneous fibrosis was induced by intracutaneous
injections of 800 ng of TGF-b1 into the neck of newborn Balb/c mice
on three consecutive days. Treatment groups (four groups of three
mice each) consisted of mice injected with TGF-b1, TGF-b1 plus
LZNP or LZNT (50 mM), and the solvent (0.1% BSA in PBS) in which
TGF-b1 had been solubilized. On day 4, mice were killed and 4-mm
punch biopsies were taken from the sites of injection for (immuno-
)histochemical analysis.
Immunohistochemistry
After fixation in 4% paraformaldehyde and embedment in paraffin,
biopsies from mouse skin were processed with the following stains:
(1) hematoxylin and eosin and (2) van Gieson stain, in which
collagen appears red; (3) for collagen staining, deparaffinized
sections were incubated with proteinase K solution (DakoCytoma-
tion GmbH, Hamburg, Germany) for 1minute, washed three times
in Tris-buffered saline solution containing 0.05% Tween 20, pH 7.6,
and consecutively stained with a rabbit antibody against collagen
type I (1:500; DPC Biermann, Bad Nauheim, Germany) for 1 hour (4)
for a-smooth muscle actin staining, sections were microwave treated
to unmask epitopes, followed by incubation with a polyclonal
antibody from Abcam (Cambridge, UK) for 30minutes. Negative
controls included incubation with control IgG at the same protein
concentration as the primary antibody, and omission of the primary
antibody.
The consecutive steps were performed using standard immuno-
peroxidase techniques following the protocol of the LSAB-2 System-
AP staining kit (DakoCytomation). Slides were incubated for
20minutes in the dark with the chromogenic substrate Fast RED,
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rinsed with, and placed for 10minutes in water, and
finally counterstained with Mayer’s hematoxylin (10 seconds)
before mounting in Faramount Aequous Mounting Medium
(DakoCytomation).
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